402 related articles for article (PubMed ID: 18030070)
1. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A
J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
[TBL] [Abstract][Full Text] [Related]
2. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
Marazzi G; Gebara O; Vitale C; Caminiti G; Wajngarten M; Volterrani M; Ramires JA; Rosano G; Fini M
Adv Ther; 2009 Apr; 26(4):455-61. PubMed ID: 19396409
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.
Di Napoli P; Di Giovanni P; Gaeta MA; D'Apolito G; Barsotti A
Am Heart J; 2007 Sep; 154(3):602.e1-5. PubMed ID: 17719313
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
Fragasso G; Palloshi A; Puccetti P; Silipigni C; Rossodivita A; Pala M; Calori G; Alfieri O; Margonato A
J Am Coll Cardiol; 2006 Sep; 48(5):992-8. PubMed ID: 16949492
[TBL] [Abstract][Full Text] [Related]
5. Role of trimetazidine in management of ischemic cardiomyopathy.
Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC
Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202
[TBL] [Abstract][Full Text] [Related]
6. [The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy].
Sisakian AS; Torgomian AL; Barkhudarian AL
Klin Med (Mosk); 2006; 84(10):55-8. PubMed ID: 17201276
[TBL] [Abstract][Full Text] [Related]
7. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
Belardinelli R; Lacalaprice F; Faccenda E; Volpe L
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):533-40. PubMed ID: 18797405
[TBL] [Abstract][Full Text] [Related]
8. Differences in management and outcome of ischemic and non-ischemic cardiomyopathy.
Ng AC; Sindone AP; Wong HS; Freedman SB
Int J Cardiol; 2008 Sep; 129(2):198-204. PubMed ID: 17706807
[TBL] [Abstract][Full Text] [Related]
9. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
Vitale C; Wajngaten M; Sposato B; Gebara O; Rossini P; Fini M; Volterrani M; Rosano GM
Eur Heart J; 2004 Oct; 25(20):1814-21. PubMed ID: 15474696
[TBL] [Abstract][Full Text] [Related]
10. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F
J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
[TBL] [Abstract][Full Text] [Related]
11. Trimetazidine shortens QTc interval in patients with ischemic heart failure.
Zemljic G; Bunc M; Vrtovec B
J Cardiovasc Pharmacol Ther; 2010 Mar; 15(1):31-6. PubMed ID: 19966175
[TBL] [Abstract][Full Text] [Related]
12. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
Belardinelli R
Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
[TBL] [Abstract][Full Text] [Related]
13. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK
Klin Med (Mosk); 2004; 82(11):15-20. PubMed ID: 15656392
[TBL] [Abstract][Full Text] [Related]
14. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
Fragasso G; Piatti Md PM; Monti L; Palloshi A; Setola E; Puccetti P; Calori G; Lopaschuk GD; Margonato A
Am Heart J; 2003 Nov; 146(5):E18. PubMed ID: 14597947
[TBL] [Abstract][Full Text] [Related]
15. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
Fragasso G; Perseghin G; De Cobelli F; Esposito A; Palloshi A; Lattuada G; Scifo P; Calori G; Del Maschio A; Margonato A
Eur Heart J; 2006 Apr; 27(8):942-8. PubMed ID: 16510466
[TBL] [Abstract][Full Text] [Related]
16. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
Fragasso G; Salerno A; Lattuada G; Cuko A; Calori G; Scollo A; Ragogna F; Arioli F; Bassanelli G; Spoladore R; Luzi L; Margonato A; Perseghin G
Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
[TBL] [Abstract][Full Text] [Related]
17. Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
Yusuf S
Herz; 1993 Dec; 18 Suppl 1():444-8. PubMed ID: 8125425
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic value of trimetazidine in patients with coronary heart disease and left ventricular dysfunction].
Multicentral Collaborative Group on Trimetazidine (Phase IV)
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Sep; 33(9):793-5. PubMed ID: 16266453
[TBL] [Abstract][Full Text] [Related]
19. [Influence of therapy schedule on hospitalization frequency and prognosis in heart failure in 3 yrs. observations].
Sidorowicz K; Tkacz E; Poloński L
Pol Merkur Lekarski; 2002 Jan; 12(67):30-5. PubMed ID: 11957798
[TBL] [Abstract][Full Text] [Related]
20. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy.
Tuunanen H; Engblom E; Naum A; Någren K; Scheinin M; Hesse B; Juhani Airaksinen KE; Nuutila P; Iozzo P; Ukkonen H; Opie LH; Knuuti J
Circulation; 2008 Sep; 118(12):1250-8. PubMed ID: 18765391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
